logo
logo
  • Home
    • Home 1
    • Home 2
    • Home 3
    • Home 4
  • Pages
    • About us
    • Partner
    • Our Team
    • Faq
    • Error
  • Career
    • Career
    • Job Description
  • Research
    • Research & Development
    • Research Details
    • Product Pipeline
    • Invester
    • Scientific Platform
  • Shop
    • Shop
    • Product Details
    • Cart Page
    • Checkout Page
  • News
    • Masonry
      • Style one
      • Style two
    • Without Grid
      • Style one
      • Style two
    • Default Layout
      • Style one
      • Style two
    • News Details
  • Contact
  • Log In /
  • Sing Up

Welcome back

To keep connected with us please login with your personal info

Create account


Or

  • Sign in with facebook
  • Sign in with google

Log In

Forget password ?
  • Sign in with facebook
  • Sign in with google
New User ?
Create a new account

Hi Dear ? Sign up to join us

Product Pipeline

  • Home
  • Product Pipeline

Building a Pipeline of Immunotherapies

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even slightly believable. If you are going to use a passage of Lorem Ipsum, you need to be sure there isn't anything embarrassing hidden in the middle of text. All the Lorem Ipsum generators on the Internet tend to repeat predefined chunks as necessary, making this the first true generator on the Internet.

It uses a dictionary of over 200 Latin words, combined with a handful of model sentence structures, to generate Lorem Ipsum which looks reasonable. The generated Lorem Ipsum is therefore always free from repetition, injected humour, or non-characteristic words etc.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2018.

Our Pipeline

Utilizing Our Proprietary Technologies to Create Life-Changing Therapies
Product Name Pre-Clinical Phase 1 Phase 2 Phase 3 Next Catalyst
Xcarti Platform

B-Cell Non-Hodgkin Lymphoma

50% Complete
Meet with regulatory authorities to discuss development plan
Xbio-101

Progesterone Resistant Endometrial Cancer

B-Cell Non-Hodgkin Lymphoma

50% Complete

Immuno-Oncology

50% Complete
Data analysis

Exploratory study of estrogen receptor and O-I biomarkers

Exploratory study of estrogen receptor and I-O biomarkers
Polyxew TM

Triple-Negative Breast Cancer

50% Complete
Exploratory study of estrogen receptor and I-O biomarkers

Our Partnership

footer logo
  • About
  • Research
  • Contact
© Jozicular All right reserved. Powered with by Zwin